Quote: BuckCYDYlong I feel I deserve some level

New Post Public Reply Private Reply Replies (0) Message Board
Goosebumps BuckCYDYLong #127010
703
Quote: BuckCYDYlong

I feel I deserve some level communication. It would be greatly appreciated before I vote to dilute my shares.



What if there isn’t enough current shares to finance the company forward to the annual shareholders meeting? Should we hold back monies / authorized shares from our company and put our company in jeopardy. Is that your fall back option? If you don’t get / demand what you suggested? Let’s be real about this. Biotech are usually funded almost exclusively by dilution because there is usually no incoming revenue. Financing is not a conditional issue that we should hold back on the company. Weigh it out… dilution or no company… hmmm?

Fact is… the company is asking us to finance our debts and trials for the rest of the year and must anticipate a lift of the hold. Our safety aggregate has to be complete or damn close by now. Things will progress nicely once lifted if we have the funds to finance the company. We go nowhere or worst if we don’t.

Or we can believe like you do and tie both hands behind the managements back and send them into the boxing ring with no way to fight back and improve this company. Tell them they missed all the opportunities because we want more information from the president and management and we deserve it before we give them shares… how smart does this sound? Is it reasonable? Sounds reasonable but is it? I don’t t think so.

We all miss the openness of the old management but the shorts are missing it the most I bet. I have that trust to believe we are on our way to greatness. I don’t need to be pumped up to believe that by the president or the management.

We should finance the company because it is really our best option for the future. Trust is a funny thing. If you don’t have it by now… might want to try another investment. Just sayin… holding back financing is a slippery slope we can’t afford to test. Vote “ FOR “ the proposals and be done with it. It’s the smart move for us all. Dilution is dilution and it’s not a dirty word. It’s a way of life with biotechs. It’s their life blood. Nobody likes it but the alternative is much worse if you short the company of money to take care of our investment. Let’s be real here. We don’t have many options other than to authorize shares.

Maybe we should not wait and just vote “ FOR “ asap because that seems like the smart thing for our investment. It’s not only the smart thing… it the right thing to do. Lets get’er done! We will all reap the benefit of being smart.





Read More: https://investorshangout.com/post/newpost/605...z7aTQMW2MG

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beverly Hills MD's Dermal Cream Wins Key Beauty Award

Updated Category News Views 2

A Surprise Win in the Beauty World Who doesn't love an underdog story, right? Beverly Hills MD has slid into the limelight with their Dermal Repair Complex snagging the award for 'Beauty Product of the Year.' Talk about sending shockwaves through the beauty industry! Now, these guys might not be a household name yet, but you better believe they've got everyone's attention...

Continue Reading
Curaleaf Expands in Florida Amid Rising Cannabis Demand

Updated Category News Views 1

Curaleaf's Bold Moves in Florida's Ganja Gold Rush Fresh out of the gate, Curaleaf is saddling up for a wild ride into Florida's cannabis frontier. They've just thrown open the doors of their latest dispensary in Riverview, cranking their statewide count up to 77. Now, isn’t that something? If you're tracking these folks, you know that bringing their nationwide total to...

Continue Reading
AI Platform Suno Sued for Exploiting Artists' Identities

Updated Category News Views 1

AI and the Music Business: A Legal Storm Brews Well, it looks like the music world’s hitting a rough patch with AI in the crosshairs. We've got Korein Tillery, a heavyweight in the legal arena, throwing down the gauntlet against Suno, an AI music-generation platform. Folks, welcome to the battleground where art meets tech and identity theft takes a whole new meaning....

Continue Reading
Rackspace Lawsuit Deadline: Investors Must Take Action

Updated Category News Views 2

Rackspace's Legal Predicament: Time for Action Alright folks, if you're holding shares of Rackspace Technology (NASDAQ:RXT), it’s time to sit up and pay attention. This is about more than bad PR or a temporary hiccup in the stock price—this is serious business. We’ve got until September 28, 2026, to decide if we’re in or out on this class action lawsuit train....

Continue Reading
Clinical Trials Services Market Set for Big Growth

Updated Category News Views 0

Eyeing a Market Surge in Clinical Trials Numbers don't lie, and they're painting a promising picture for the clinical trials services market with a solid 8% growth forecasted annually till 2031. From a modest $66.20 billion in 2026, we're looking at ballooning to a hefty $97.41 billion by 2031. What’s cooking? Let me dish it out for you. Key Drivers and Dynamics North...

Continue Reading
Art and Science Blend in Dr. De La Cruz's Approach

Updated Category News Views 2

Redefining Aesthetic Surgery: An Artistic Approach The world of plastic surgery is often seen through the lens of beauty and symmetry, but for Dr. Emmanuel De La Cruz, it's like staring into a whole different universe. This Houston-based plastic surgeon isn't just removing fat—he's reshaping the human canvas with the eye of a sculptor. Beyond the Standard Cut and Snip...

Continue Reading
IVD Study Success: Hybrid Monitoring Boosts Oversight

Updated Category News Views 1

New Strategies for IVD Clinical Studies It's high time we addressed the tangled web of managing in vitro diagnostic (IVD) clinical studies. We're talking about walking a tightrope where sponsors have to juggle regulatory scrutiny, data integrity, and operational efficiency—all while pushing innovation. Simply put, the old ways of doing things just aren't cutting it...

Continue Reading
CAPR Faces Lawsuit and FDA Delay: Investor Alert

Updated Category News Views 1

Trouble Brewin' for Capricor Investors Buckle up, folks. Capricor Therapeutics (NASDAQ: CAPR) is caught in a storm, facing not just the lengthy arm of law with a securities class action, but also a seemingly endless wait with the FDA's decision on their lead product. We're talking serious implications for anyone with skin in the game. The FDA's Delayed Blessing So the...

Continue Reading
Orbis Celebrates 20 Years of Eye Care in Macau

Updated Category News Views 2

Celebrating Two Decades of Eye Health Innovation Orbis, a name synonymous with eye care worldwide, has hit a remarkable milestone. Celebrating two decades of commitment to eye health in Macau, they've rolled out their Flying Eye Hospital with a mission of profound impact. This isn't just about a fancy airplane; it’s about real, lasting change through training projects...

Continue Reading
Faruqi & Faruqi Urge Wix Investors to Act Now

Updated Category News Views 3

Ticking Clock for Wix Investors' Legal Moves The buzz in the stock market is louder than a bull on Wall Street, especially if you're tangled up with Wix.com Ltd. (NASDAQ: WIX). We've got Faruqi & Faruqi, LLP laying down serious advice: move fast or maybe lose your spot in line. The deadline to noodle over your position as a lead plaintiff in their federal securities class...

Continue Reading

Top 5 Most Recently Viewed Articles

Executive Shifts at Title Resources Group: Key Leadership Updates

Updated Category News Views 233

Leadership Changes at Title Resources Group Title Resources Group (TRG), a leading title insurance underwriter, is undergoing an important executive transition. Kevin Wall is set to be appointed as the new Chief Executive Officer (CEO), succeeding J. Scott McCall, who will transition to the role of Vice Chairman of the Board of Directors. This strategic move, reflecting...

Continue Reading
Bear Stewart Recall: Soy Allergy Alert Shakes Confidence

Updated Category News Views 56

Undeclared Ingredients: Not Just Another Casual Glitch Well, here we go again. Bear Stewart LLC's latest revelation sends alarm bells ringing for anyone with a nose for allergic disorders. Their Bakr Brown Butter Chocolate Chunk Ready To Bake Cookie Dough found its way to store shelves with an ingredient that can cause mayhem for many – soy. Imagine thinking you’re...

Continue Reading
Exploring the Impact of Inclusivity in Global Advertising

Updated Category News Views 134

The Importance of Inclusive Advertising In today's dynamic advertising landscape, inclusivity plays a critical role in how brands connect with their audiences. Inclusivity isn't just a buzzword; it's becoming essential for brands aiming to resonate with diverse demographics, reflecting the world we live in. XR Extreme Reach, a leading global technology company, has taken...

Continue Reading
Suburban Propane Partners with Local Organizations for Community Support

Updated Category News Views 117

Suburban Propane's Commitment to Community Well-being Suburban Propane Partners, L.P. (NYSE: SPH), a leading provider of propane and renewable energy solutions, is dedicated to making a positive impact in local communities. Recently, they partnered with Sharing House, a community organization focused on assisting those in need. This collaboration aimed to gather essential...

Continue Reading
GoHealth Inc. Achieves New Heights with Stock Performance

Updated Category News Views 227

GoHealth's Significant Stock Surge Recently, GoHealth Inc. (GOCO) has made headlines as it reached a remarkable milestone by hitting a 52-week high of $14.94. This achievement illustrates a substantial 12% gain over the past week and a phenomenal 40% surge over the last six months. Investors and market analysts have been captivated by these developments, considering the...

Continue Reading